Active Ingredient: Dapagliflozin Propanediol Monohydrate (equivalent to 5 mg dapagliflozin)
Manufacturer: AstraZeneca Pharmaceuticals LP
Registration Number (MAL): MAL14015014ARZ
Type 2 Diabetes Mellitus: For improving glycaemic control in adults, either as monotherapy or in combination with other antidiabetic agents.
Chronic Heart Failure: For the treatment of symptomatic chronic heart failure in adults.
Chronic Kidney Disease: For the treatment of chronic kidney disease in adults.
Dosage: 10 mg once daily, taken with or without food.
Administration: Swallow the tablet whole with water; do not chew, crush, or split.
Special Populations: No dose adjustment is required based on age. For patients with renal impairment, efficacy decreases as eGFR falls below 45 mL/min. Alternative therapies may be considered if eGFR is below this threshold.
Malaysia
